BLATT LAWRENCE 4

What Happened

• Lawrence Blatt, President, CEO and Director of Aligos Therapeutics (ALGS), was granted a derivative award of 105,840 shares on March 9, 2026. The award was reported at $0.00 per share (typical for compensation grants) and is a grant/award (Form 4 code A), not an open-market purchase or sale.

Key Details

• Transaction date: March 9, 2026; filing date: March 11, 2026 (filed timely).
• Security: 105,840 shares (derivative award) acquired at $0.00.
• Shares owned after transaction: not specified in the filing.
• Vesting: per footnote, 1/48th of the shares vest monthly over 48 months starting March 9, 2026; fully vested on the fourth anniversary assuming continued service.
• No 10b5-1 plan, tax-withholding, or cashless-sale indicated in the filing.

Context

• This was a compensation grant (award), not a purchase or sale — such grants are common for executives and reflect compensation rather than an immediate market bet. The award vests over time, meaning value is tied to continued service and future company performance.